152 related articles for article (PubMed ID: 30605942)
1. A Rare Cause of Uveitis: Vemurafenib.
Sızmaz S; Görkemli N; Esen E; Demircan N
Turk J Ophthalmol; 2018 Dec; 48(6):323-325. PubMed ID: 30605942
[TBL] [Abstract][Full Text] [Related]
2. Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma.
Eser Öztürk H; Süllü Y
Turk J Ophthalmol; 2020 Mar; 50(1):50-52. PubMed ID: 32167264
[TBL] [Abstract][Full Text] [Related]
3. Development of Acute Vogt-Koyanagi-Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma.
Apivatthakakul A; Kunavisarut P; Rothova A; Pathanapitoon K
Ocul Immunol Inflamm; 2020 Apr; 28(3):505-508. PubMed ID: 31161956
[No Abstract] [Full Text] [Related]
4. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib.
Guedj M; Quéant A; Funck-Brentano E; Kramkimel N; Lellouch J; Monnet D; Longvert C; Gantzer A; Brézin AP
JAMA Ophthalmol; 2014 Dec; 132(12):1421-5. PubMed ID: 25125216
[TBL] [Abstract][Full Text] [Related]
5. Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.
Wolf SE; Meenken C; Moll AC; Haanen JB; van der Heijden MS
BMC Cancer; 2013 Dec; 13():561. PubMed ID: 24289205
[TBL] [Abstract][Full Text] [Related]
6. [Drug-induced uveitis with vemurafenib: Report of two cases].
Rivoal Y; Bailleul H; Miocque S; Quintyn JC
J Fr Ophtalmol; 2022 Oct; 45(8):e378-e380. PubMed ID: 35570167
[No Abstract] [Full Text] [Related]
7. Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma.
Fusumae T; Kamiya K; Maekawa T; Komine M; Murata S; Inoda S; Takahashi R; Kawashima H; Ohtsuki M
J Dermatol; 2018 Jun; 45(6):e159-e160. PubMed ID: 29314171
[No Abstract] [Full Text] [Related]
8. Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma - Case Series and Review.
Fierz FC; Meier F; Chaloupka K; Böni C
Klin Monbl Augenheilkd; 2016 Apr; 233(4):540-4. PubMed ID: 27116532
[TBL] [Abstract][Full Text] [Related]
9. Bilateral Drug-Induced Uveitis and Epiretinal Membrane during the Treatment of a Metastatic Cutaneous Melanoma.
Mozo Cuadrado M; Tabuenca Del Barrio L; Compains Silva E
Ocul Immunol Inflamm; 2021 Apr; 29(3):543-545. PubMed ID: 31755788
[No Abstract] [Full Text] [Related]
10. Uveitic macular oedema after treatment with vemurafenib.
Fonollosa A; Mesquida M; Adan A
Acta Ophthalmol; 2015 Dec; 93(8):e686-7. PubMed ID: 25683228
[No Abstract] [Full Text] [Related]
11. ACUTE EXUDATIVE PARANEOPLASTIC POLYMORPHOUS VITELLIFORM MACULOPATHY DURING VEMURAFENIB AND PEMBROLIZUMAB TREATMENT FOR METASTATIC MELANOMA.
Sandhu HS; Kolomeyer AM; Lau MK; Shields CL; Schuchter LM; Nichols CW; Aleman TS
Retin Cases Brief Rep; 2019 Spring; 13(2):103-107. PubMed ID: 28614138
[TBL] [Abstract][Full Text] [Related]
12. [Vogt-Koyanagi-Harada syndrome in the setting of vemurafenib therapy for metastatic melanoma: a case report].
Ren XT; Guo T; Yang F; Wu WY; Dou HL; Li XM
Zhonghua Yan Ke Za Zhi; 2022 Nov; 58(11):925-928. PubMed ID: 36348532
[TBL] [Abstract][Full Text] [Related]
13. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
14. Lamotrigine-induced tubulointerstitial nephritis and uveitis-atypical Cogan syndrome.
Kolomeyer AM; Kodati S
Eur J Ophthalmol; 2015 Dec; 26(1):e14-6. PubMed ID: 26350991
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
16. Bilateral uveitis and macular edema induced by Nivolumab: a case report.
Theillac C; Straub M; Breton AL; Thomas L; Dalle S
BMC Ophthalmol; 2017 Dec; 17(1):227. PubMed ID: 29195497
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib-induced plantar hyperkeratosis.
Bashline BR; Bedocs PM
Cutis; 2018 Sep; 102(3):E19-E21. PubMed ID: 30372722
[No Abstract] [Full Text] [Related]
18. Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure.
Arenbergerova M; Mrazova I; Horazdovsky J; Sticova E; Fialova A; Arenberger P
J Eur Acad Dermatol Venereol; 2017 May; 31(5):e253-e254. PubMed ID: 27739125
[No Abstract] [Full Text] [Related]
19. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
Choe CH; McArthur GA; Caro I; Kempen JH; Amaravadi RK
Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
[TBL] [Abstract][Full Text] [Related]
20. [Bilateral uveitis associated with protein kinase inhibitor-based treatment of skin melanoma (case study)].
Udovichenko EV; Danilova LP; Sorokin EL; Fil AA
Vestn Oftalmol; 2023; 139(3):69-75. PubMed ID: 37379111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
